Pediatrix Medical Group reiterates 2024 Adj. EBITDA guidance of $200M-$220M, portfolio optimization with $30M impact

Pediatrix Medical Group, Inc.

Company exiting office-based practices and primary/urgent care by end of 2024.
Annualized Adj. EBITDA impact of portfolio optimization ~$30M (based on 2023 results).
Reiterates 2024 Adj. EBITDA guidance range of $200M to $220M, including in-year impact.
Focus on operating efficiency and margin stabilization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.